Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 169 of 6351
-
New pill targets rare gene in Hard-to-Treat cancers
Disease control CompletedThis research study is done to test the safety of the drug larotrectinib in adult cancer patients. The drug may be used to treat cancer with a change in a particular gene (NTRK1, NTRK2 or NTRK3), because it blocks the action of these genes in cancer cells. The study also investig…
Phase 1 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New pill could keep BRCA breast cancer from coming back
Disease control OngoingOlaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New pill could beat chemo for BRCA breast cancer
Disease control CompletedThis open label, randomised, controlled, multi-centre phase III study will assess the efficacy and safety of single agent olaparib vs standard of care based on physician's choice of capecitabine, vinorelbine or eribulin in metastatic breast cancer patients with gBRCA 1/2 mutation…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Triple-Drug attack on tough hodgkin lymphoma shows promise in early trial
Disease control OngoingThis phase I/II trial studies the side effects and best dose of ipilimumab and nivolumab when given together with brentuximab vedotin, and how well they work in treating patients with Hodgkin lymphoma that has returned after a period of improvement (recurrent) or has not responde…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a faster chemo schedule beat tough testicular cancer?
Disease control Recruiting nowThe purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic germ cell tumours.
Phase 3 • Sponsor: University of Sydney • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Could a Man's own stem cells restore his fertility?
Disease control Recruiting nowThis is an open label, single arm, single center investigation to assess the safety and efficacy of purified adult autologous, bone marrow derived, highly specialized, differentiation specific into spermatogonial lineages, and mesenchymal stem cells injected into the seminiferous…
Phase 1/2 • Sponsor: Stem Cells Arabia • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Mind-Controlled tech: brain implant gives hope to paralyzed patients
Disease control Recruiting nowThe purpose of this research study is to demonstrate the safety and efficacy of using two CRS Arrays (microelectrodes) for long-term recording of brain motor cortex activity and microstimulation of brain sensory cortex.
Sponsor: Michael Boninger • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Can changing the order of rectal cancer treatment boost survival?
Disease control OngoingThe study is designed to test the hypothesis that patients with Locally advanced rectal cancer ( LARC) treated with Total neoadjuvant therapy (TNT) and Total mesorectal excision (TME) or Non-operative management (NOM) will have an improved 3-year disease-free survival (DFS) compa…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New hope for tough hepatitis c: 4-Drug cocktail aims for cure in Non-Responders
Cure CompletedSuccess rates, after retreatment with Peg-Interferon/Ribavirin bitherapy, in patients infected with HCV (hepatitis C virus) genotype 4 and non-responders to a first standard treatment, are disappointing. The association of Asunaprevir and Daclatasvir in combination with the stand…
Phase 2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Cure
Last updated Jun 27, 2026 12:06 UTC
-
New hope for men with prostate cancer: drug delays spread by months
Disease control CompletedThe purpose of this study is to assess the safety and efficacy of enzalutamide in patients with non metastatic prostate cancer.
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Could a parasite drug fight childhood brain tumors?
Disease control OngoingThis is a study to determine the safety and efficacy of the drug, mebendazole, when used in combination with standard chemotherapy drugs for the treatment of pediatric brain tumors. Mebendazole is a drug used to treat infections with intestinal parasites and has a long track reco…
Phase 1/2 • Sponsor: Julie Krystal • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Promising drug may delay prostate cancer spread in High-Risk patients
Disease control OngoingThe purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer.
Phase 3 • Sponsor: Aragon Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Mind-Controlled tablets give voice to the paralyzed
Symptom relief Recruiting nowThe investigators objective is to run human clinical trials in which brain activity recorded through a "brain-chip" implanted in the human brain can be used to provide novel communication capabilities to severely paralyzed individuals by allowing direct brain-control of a compute…
Sponsor: Richard A. Andersen, PhD • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
New drug cocktail aims to tackle KRAS lung cancer
Disease control OngoingThe purpose of this study is to assess the efficacy of selumetinib in combination with docetaxel (75mg/m2) vs placebo in combination with docetaxel (75mg/m2) in patients with locally advance or metastatic NSCLCs that harbor mutations of KRAS. This study will also assess the PK, s…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Could a drug combo keep High-Risk breast cancer from coming back?
Disease control OngoingRATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Everolimus may stop t…
Phase 3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug cocktail shows promise against tough skin cancer
Disease control CompletedThis is 2-part, randomized, open label, multi-center, parallel group, phase III study comparing the efficacy and safety of LGX818 plus MEK162 to vemurafenib and LGX818 monotherapy in patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation. A tot…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Brain 'Radio' tunes into Depression's neural signals
Disease control OngoingThe goal of this study is to use the Activa Primary Cell + Sensing (PC+S) device to study Latent Field Potential (LFP) in the brains of people with Treatment Resistant Depression (TRD) before and during active stimulation. The ultimate goal is to understand the neural network tha…
Sponsor: Emory University • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New pill could keep ovarian cancer at bay for BRCA patients
Disease control OngoingOlaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy.
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New antibody drug aims to tame Hard-to-Control asthma
Disease control CompletedThis randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab in participants with asthma whose disease remains uncontrolled despite daily treatment with inhaled corticosteroid (ICS) therapy and at least…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Can a stem cell transplant fix a rare genetic immune disorder?
Disease control Recruiting nowBackground: \- GATA2 deficiency is a disease caused by mutations in the GATA2 gene. It can cause different types of leukemia and other diseases. Researchers want to see if a stem cell transplant can be used to treat this condition. A stem cell transplant will give stem cells fro…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC